Dr. Reddys Laboratories Ltd.

Dr Reddy’s Lab is currently trading at Rs. 1899.00, up by 10.40 points or 0.55% from its previous closing of Rs. 1888.60 on the BSE.

The scrip opened at Rs. 1880.00 and has touched a high and low of Rs. 1902.00 and Rs. 1872.25 respectively. So far 4,398 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1912.90 on 11-Dec-2012 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1895.40 and Rs. 1817.05 respectively. The current market cap of the company is Rs. 32,237 crore.

The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 39.75% and 17.76% respectively.

In the process of acquiring 100% stake in Netherlands-based specialty pharmaceutical company OctoPlus NV, Dr Reddy’s Laboratories has, so far, acquired 79.4% stake of Octoplus. Of the aforementioned stake, the company has bought 15.9% shares (83,59,858 shares) through open market and 63.5% shares (3,34,48,839 shares) were committed by certain members of the OctoPlus Board and other shareholders though irrevocable undertaking.

The entire acquisition is expected to be completed by the end of the current financial year. As per the agreement, Dr Reddy’s made an open offer to purchase all outstanding shares of OctoPlus at an offer price of 0.52 euro in cash for each share.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.